Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-604-9
CAS number: 1163-19-5
The first work on BDE-209’s ADME properties
was reported in the early 1970s (Norris et al. 1974, 1973, 1975). Norris
et al. (1975) administered a single dose of 1.0 mg/kg 14CBDE- 209
(specific activity: 1.1 μCi/mg; purity not specified) by gavage in corn
oil to 3 male and 3 female Sprague-Dawley rats. 14C-activity in expired
air and urine, measured at 24-h intervals over a 16-day period, was <1%.
The principal route of excretion was the feces, and both genders
eliminated the 14C-activity at similar rates. Within the first 24 h
postdosing, 90.6% of the administered dose was detected in the feces,
and >99% of the 14C-activity was accounted for by day 2. Tissues
(adipose, heart, liver, pancreas, skin) on day 16 post-dosing showed no
14C-label with the exception of the adrenal (0.01% of the dose/g of
tissue) and spleen (0.06%). The 14C-activity in these 2 tissues was at
the limit of detection. The half-life of the disappearance of
14C-activity from the body of treated rats was <24 h.
Norris et al. (1974, 1975) also reported
total bromine concentrations, using neutron activation analysis, in the
adipose tissue, kidney, liver, serum, skeletal muscle, and testes in
male and female Sprague-Dawley rats maintained on diets providing 0,
0.01, 0.1, and 1.0 mg of a former commercial product, i.e., FR-300-BA
(The Dow Chemical Company, Midland, MI, USA)/kg-day for 3, 6, or 12
months. FR-300-BA was composed of 77.4% BDE-209, 21.8% nonabromodiphenyl
ether (nonaBDE), and 0.8% octabromodiphenyl ether (octaBDE). After 180
days of treatment, bromine concentrations in liver, kidney, skeletal
muscle, serum, and testes of treated rats were comparable to that of
controls. Bromine concentrations in adipose tissue from treated rats (~3
μg bromine/g) were increased, compared to controls (~1 μg bromine/g).
However, after 12 months of treatment, liver and adipose tissue bromine
concentrations were comparable to controls. In addition, elimination of
bromine from liver and adipose tissue was followed in male
Sprague-Dawley rats maintained for 90 days on diets providing 1.0 mg
FR-300-BA/kg-day and afterward fed control diet. Adipose tissue, kidney,
liver, and serum were analyzed for bromine by neutron activation
analysis. On recovery day 0, measurable levels of bromine were reported
in the liver (~5 μg bromine/g) compared to controls (>~2 but <4 μg
bromine/g); no difference in bromine content in kidney or serum was
reported between the controls and treated rats. After 10 days on the
control diet, bromine concentrations in the liver of treated rats were
comparable to controls. Adipose bromine levels in the treated group
(~2.5–4 µg bromine/g) were higher than the controls (~0–2 µg bromine/g)
during the recovery period.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again